News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
